- Microbot Medical Shares Status Following Recent Geopolitical Events
- Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
- Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
- Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
- Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
- Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
- Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic
- Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study
- Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities
- Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process
More ▼
Key statistics
As of last trade Microbot Medical Inc (MBOT:NAQ) traded at 0.875, 1.73% above its 52-week low of 0.8601, set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.90 |
---|---|
High | 0.90 |
Low | 0.865 |
Bid | 0.865 |
Offer | 0.8699 |
Previous close | 0.8799 |
Average volume | 161.46k |
---|---|
Shares outstanding | 14.40m |
Free float | 14.16m |
P/E (TTM) | -- |
Market cap | 12.67m USD |
EPS (TTM) | -1.08 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 18:43 BST.
More ▼